JNJ

227.87

-0.96%↓

UNH

370.05

-0.18%↓

TMO

470.4

-1.31%↓

ISRG

459.45

+0.88%↑

ABT

89.8

-0.71%↓

JNJ

227.87

-0.96%↓

UNH

370.05

-0.18%↓

TMO

470.4

-1.31%↓

ISRG

459.45

+0.88%↑

ABT

89.8

-0.71%↓

JNJ

227.87

-0.96%↓

UNH

370.05

-0.18%↓

TMO

470.4

-1.31%↓

ISRG

459.45

+0.88%↑

ABT

89.8

-0.71%↓

JNJ

227.87

-0.96%↓

UNH

370.05

-0.18%↓

TMO

470.4

-1.31%↓

ISRG

459.45

+0.88%↑

ABT

89.8

-0.71%↓

JNJ

227.87

-0.96%↓

UNH

370.05

-0.18%↓

TMO

470.4

-1.31%↓

ISRG

459.45

+0.88%↑

ABT

89.8

-0.71%↓

Search

Twist Bioscience Corp

Abrir

SetorSaúde

60.32 1.62

Visão Geral

Variação de preço das ações

24h

Atual

Mín

57.53

Máximo

60.64

Indicadores-chave

By Trading Economics

Rendimento

-3.4M

-31M

Vendas

4.7M

104M

Margem de lucro

-29.419

Funcionários

979

EBITDA

-3.2M

-24M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-3.35% downside

Dividendos

By Dow Jones

Próximos Ganhos

4 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.1B

3.7B

Abertura anterior

58.7

Fecho anterior

60.32

Sentimento de Notícias

By Acuity

50%

50%

186 / 347 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Twist Bioscience Corp Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

30 de abr. de 2026, 23:08 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 23:07 UTC

Ganhos

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:20 UTC

Ganhos

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 23:47 UTC

Conversa de Mercado

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 de abr. de 2026, 23:27 UTC

Conversa de Mercado

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 de abr. de 2026, 23:22 UTC

Ganhos

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 de abr. de 2026, 23:20 UTC

Conversa de Mercado

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 de abr. de 2026, 22:52 UTC

Ganhos

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 de abr. de 2026, 22:33 UTC

Ganhos

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 de abr. de 2026, 22:32 UTC

Ganhos

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 de abr. de 2026, 22:24 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 de abr. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

30 de abr. de 2026, 22:11 UTC

Conversa de Mercado

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 de abr. de 2026, 22:05 UTC

Ganhos

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 de abr. de 2026, 21:57 UTC

Ganhos

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 de abr. de 2026, 21:56 UTC

Ganhos

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 de abr. de 2026, 21:55 UTC

Ganhos

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 de abr. de 2026, 21:54 UTC

Ganhos

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 de abr. de 2026, 21:53 UTC

Ganhos

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 de abr. de 2026, 21:49 UTC

Ganhos

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Comparação entre Pares

Variação de preço

Twist Bioscience Corp Previsão

Preço-alvo

By TipRanks

-3.35% parte inferior

Previsão para 12 meses

Média 54.8 USD  -3.35%

Máximo 58 USD

Mínimo 50 USD

Com base em 6 analistas de Wall Street que oferecem metas de preço de 12 meses para Twist Bioscience Corp - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

6 ratings

6

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

31.56 / 38.6884Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

186 / 347 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat